Close Menu

Georgetown University

The drug, LP-184, demonstrated increased efficacy against prostate cancer cells overexpressing PTGR1 in preclinical studies and inspired further research.

Informaticians from Georgetown and other major cancer centers expect their technology to bring precision oncology services to community hospitals and clinics.